Aktiia, a blood pressure intelligence platform, has completed an oversubscribed USD 42m Series-B funding-round, bringing the company's total funding to date to USD 100m. The proceeds will accelerate Aktiia's expansion into new markets. The round was co-led by Earlybird Health and Wellington Partners with new investors Kfund and naturalX Health Ventures, and participation from existing investors redalpine, Khosla Ventures, Molten Ventures, Translink Capital and Verve Ventures.
The VISCHER team advising the co-lead and other new investors in this transaction included Matthias Staehelin (Partner, Corporate/M&A), Vincent S. Reardon (Managing Associate, Corporate/M&A), Timothy Woodtli (Senior Associate, Corporate/M&A), Lucas Sturzenegger (Associate, Corporate/M&A), Rahel Widmer (Associate, Corporate/M&A), Stefanie Havalda (Junior Associate), Celine Kappler (Junior Associate), and Nadia Tarolli (Partner, Tax), Nora Heuberger (Managing Associate, Tax) and Diego Anzante (Associate, Tax).
Author: Vincent S. Reardon
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]
Nadia Tarolli Schmidt
Attorney at Law, Swiss Certified Tax Expert
- Partner
- +41 58 211 33 54
- [email protected]
